Values First Advisors Inc. trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 55.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,740 shares of the company’s stock after selling 21,179 shares during the quarter. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $494,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. Polar Capital Holdings Plc raised its position in shares of Mirum Pharmaceuticals by 27.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after acquiring an additional 250,000 shares in the last quarter. Raymond James & Associates increased its position in Mirum Pharmaceuticals by 57.1% during the 3rd quarter. Raymond James & Associates now owns 106,207 shares of the company’s stock valued at $3,356,000 after buying an additional 38,619 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Mirum Pharmaceuticals by 210.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock valued at $7,096,000 after buying an additional 152,287 shares in the last quarter. Rafferty Asset Management LLC increased its position in Mirum Pharmaceuticals by 18.4% during the 3rd quarter. Rafferty Asset Management LLC now owns 137,205 shares of the company’s stock valued at $4,336,000 after buying an additional 21,312 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Mirum Pharmaceuticals by 202.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 114,109 shares of the company’s stock valued at $3,606,000 after buying an additional 76,369 shares in the last quarter.
Insider Activity at Mirum Pharmaceuticals
In other Mirum Pharmaceuticals news, COO Peter Radovich sold 1,408 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.03, for a total transaction of $39,466.24. Following the completion of the sale, the chief operating officer now owns 36,485 shares of the company’s stock, valued at $1,022,674.55. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Peter Radovich sold 1,408 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.03, for a total transaction of $39,466.24. Following the completion of the transaction, the chief operating officer now directly owns 36,485 shares in the company, valued at $1,022,674.55. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Lara Longpre sold 1,019 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.04, for a total value of $28,572.76. Following the transaction, the insider now owns 105,254 shares of the company’s stock, valued at $2,951,322.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,202 shares of company stock valued at $359,119. 24.06% of the stock is currently owned by insiders.
Mirum Pharmaceuticals Price Performance
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.12 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. JMP Securities boosted their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, March 14th. Raymond James dropped their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. SVB Leerink lowered their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. HC Wainwright upped their target price on Mirum Pharmaceuticals from $45.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $52.11.
Check Out Our Latest Stock Analysis on MIRM
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Read More
- Five stocks we like better than Mirum Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Learn Technical Analysis Skills to Master the Stock Market
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is the Australian Securities Exchange (ASX)
- Disney Stock Catches 3 Upgrades In a Single Week
Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.